Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Hamada, S. Takuya, K. Mizuno, I. Higashimoto, H. Inoue (Kagoshima, Japan). Elevated serum B cell activating factor belonging to the TNF family (BAFF) in interstitial lung diseases associated with collagen vascular disease. Eur Respir J 2012; 40: Suppl. 56, 706

Member's Comments

No comment yet.

Related content which might interest you: Resistance of BAL immune cells to apoptosis in interstitial lung diseases (ILD) with high local tumor necrosis factor-α (TNFα) levels as a possible consequence of common TNF receptor type 2 expression Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008 Overexpression of B cell activating factor (BAFF) in peripheral lung of COPD patients Source: Annual Congress 2009 - Pathology and immunology of COPD Year: 2009 Elevated integrin ?5 expression in idiopathic pulmonary fibrosis (IPF) derived fibroblasts is linked to paracrine TNF-a signaling Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017 Increased intraalveolar level of soluble endothelial protein C receptor in patients with interstitial lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 319s Year: 2004 B cell activating factor belonging to the TNF family might be a useful biomarker in interstitial lung diseases associated with connective tissue diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 The influence of sera from interstitial lung diseases (ILD) patients on human mononuclear cells (MNC) production of vascular endothelial growth factor (VEGF) Source: Eur Respir J 2004; 24: Suppl. 48, 553s Year: 2004 Serum levels of vascular endothelial growth factor (VEGF) are elevated in patients with acute exacerbated COPD Source: Eur Respir J 2005; 26: Suppl. 49, 350s Year: 2005 Hepatocyte growth factor (HGF) expression in bronchoveolar lower (BAL) does not confirm its anti-fibrotic activity in interstitial lung diseases (ILD) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Increased binding activity of hypoxia inducible factor (HIF)-1α to vascular endothelial growth factor (VEGF) promoter region mediates enhanced vascular permeability in the lung of cystic fibrosis (CF) patients Source: Eur Respir J 2003; 22: Suppl. 45, 173s Year: 2003 Increased vascular endothelial growth factor (VEGF) secretion from activated T cells in COPD Source: Annual Congress 2007 - Cell-based tissue modulation: the good and the ugly? Year: 2007 Differential expression of stromal cell derived factor-1/CXC chemokine receptor 4 (SDF-1/CXCL12 – CXCR4) biological axis between idiopathic pulmonary fibrosis and interstitial pneumonia associated with collagen vascular disease: a bronchoalveolar la Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Levels of plasma tumour necrosis factor and soluble tumour necrosis factor receptor in patients with COPD and its relation to glucocorticoid receptor levels Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Expression of insulin-growth factor-I (IGF-I) in alveolar lymphocytes (AL) in interstitial lung diseases (ILD). Potential functions of AL-derived IGF Source: Annual Congress 2005 - Progresses in lung fibrosis Year: 2005 Expression of angiogenic growth factors and stromal cell derived factor-1/CXC chemokine receptor 4 (SDF-1/CXCL12 – CXCR4) biological axis in idiopathic pulmonary fibrosis: a lung tissue study Source: Annual Congress 2008 - New insights into the pathogenesis of idiopathic pulmonary fibrosis and sarcoidosis Year: 2008 Transforming growth factor B1 polymorphism and serum levels in interstitial lung diseases Source: International Congress 2015 – New insights into IIPs Year: 2015 Down-regulation of inhibitory of growth family member 4(ING4) in idiopathic pulmonary fibrosis (IPF). Correlation with disease progression Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009 Broncholaveolar lavage (BAL) lymphocytes from patients with interstitial lung diseases (ILD) produce hepatocyte growth factor (HGF) Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 Fas Ligand (FasL) expressed on alveolar lymphocytes (AL) plays role in progression of interstitial lung diseases (ILD) but not in local induction of immune cells apoptosis Source: Eur Respir J 2005; 26: Suppl. 49, 542s Year: 2005 Production of a novel isoform of vascular endothelial growth factor (VEGF) by the normal human lung Source: Eur Respir J 2006; 28: Suppl. 50, 822s Year: 2006 Serum levels of vascular endothelial growth factor in lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004